Pfizer recalls valsartan drug after possible carcinogen present 11-Feb-2019 By Maggie Lynch Pfizer Japan recalls its high blood pressure drug containing the API valsartan after possible carcinogenic impurities were found.
US FDA reveals valsartan impurity caused by reusing solvents 28-Jan-2019 By Ben Hargreaves FDA provided an update on its valsartan contamination investigation and suggested it had discovered two possible causes of the carcinogenic impurities.